By a News Reporter-Staff News Editor at Cardiovascular Week -- Research findings on Health and Medicine are discussed in a new report. According to news reporting out of Quebec City, Canada, by NewsRx editors, research stated, "ObjectivesTo demonstrate the feasibility of transfemoral transcatheter aortic valve replacement (TAVR) with the 29 mm Edwards SAPIEN XT valve and Novaflex + delivery system through a 20F expandable sheath (eSheath, Edwards Lifesciences, USA). In addition, to describe the use of the Novaflex + delivery system and expandable sheath."
Our news journalists obtained a quote from the research from the University of Montreal, "BackgroundTAVR has undergone significant advances in device technology resulting in smaller profile sheaths and delivery systems, allowing transfemoral delivery of a 29 mm valve. MethodsTwelve patients underwent transfemoral TAVR with the 29 mm Edwards SAPIEN XT valve and Novaflex + delivery system through a 20F expandable sheath. Baseline clinical and procedural characteristics are evaluated. In-hospital and 30-day outcomes are reported according to Valve Academic Research Consortium criteria. ResultsAll patients were male with a mean aortic annulus diameter of 25.0 1.1 mm and 25.9 +/- 1.2 mm, on transesophageal echocardiography and multidetector computerized tomography, respectively. Mean iliofemoral minimal luminal diameter (MLD) was 8.0 +/- 0.8 mm. Successful deployment of the valve occurred in 11 out of 12 patients. Valve embolization occurred in one patient. Aortic valve area increased from 0.7 +/- 0.2 to 2.0 +/- 0.5 cm(2) (P < 0.001). There were two major vascular complications; however, there were no in-hospital or 30-day neurological events, need for pacemaker insertion, or mortality."
According to the news editors, the research concluded: "ConclusionsTransfemoral TAVR with the 29 mm Edwards SAPIEN XT valve and Novaflex + delivery system through a 20F expandable sheath was feasible with acceptable short-term outcomes."
For more information on this research see: First-in-Man Transfemoral Transcatheter Aortic Valve Replacement With the 29 mm Edwards SAPIEN XT Valve. Catheterization and Cardiovascular Interventions, 2013;82(4):664-670. Catheterization and Cardiovascular Interventions can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Catheterization and Cardiovascular Interventions - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1522-726X)
Our news journalists report that additional information may be obtained by contacting M. Freeman, University of Montreal, Center Hosp, Dept. of Cardiol, Quebec City, PQ, Canada. Additional authors for this research include J. Rodes-Cabau, M. Urena, R. DeLarochelliere, E. Dumont, J.B. Masson, A.B. Willson, R.K. Binder, S. Toggweiler, J. Leipsic, D.A. Wood and J.G. Webb (see also Health and Medicine).
Keywords for this news article include: Canada, Hospital, Quebec City, Health and Medicine, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC